Mast Therapeutics Inc (MSTX) Lowered to Hold at Maxim Group
Mast Therapeutics Inc (NASDAQ:MSTX) was downgraded by stock analysts at Maxim Group from a “buy” rating to a “hold” rating in a note issued to investors on Wednesday.
MSTX has been the topic of a number of other reports. Roth Capital restated a “buy” rating and set a $2.00 target price on shares of Mast Therapeutics in a research report on Friday, July 15th. Zacks Investment Research upgraded shares of Mast Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, August 30th. Finally, Canaccord Genuity restated a “buy” rating and set a $3.00 target price on shares of Mast Therapeutics in a research report on Thursday, July 28th.
Shares of Mast Therapeutics (NASDAQ:MSTX) traded down 81.525% on Wednesday, reaching $0.109. 93,897,730 shares of the company were exchanged. Mast Therapeutics has a 12 month low of $0.11 and a 12 month high of $0.71. The stock’s market capitalization is $23.09 million. The stock has a 50 day moving average price of $0.46 and a 200-day moving average price of $0.38.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/mast-therapeutics-inc-mstx-lowered-to-hold-at-maxim-group.html
Mast Therapeutics (NASDAQ:MSTX) last released its earnings results on Tuesday, August 9th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.01. On average, equities analysts expect that Mast Therapeutics will post ($0.21) EPS for the current fiscal year.
A hedge fund recently raised its stake in Mast Therapeutics stock. Vanguard Group Inc. boosted its position in shares of Mast Therapeutics Inc (NASDAQ:MSTX) by 18.2% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 5,996,047 shares of the company’s stock after buying an additional 923,507 shares during the period. Vanguard Group Inc. owned 3.11% of Mast Therapeutics worth $2,818,000 as of its most recent filing with the SEC.
About Mast Therapeutics
Receive News & Ratings for Mast Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mast Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.